The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation
Open accessAbstract
Background— Pharmacogenetic-guided dosing of warfarin is a promising application of “personalized medicine” but has not been adequately tested in randomized trials. Methods and Results— Consenting patients (n=206) being initiated on warfarin were randomized to pharmacogenetic-guided or standard dosing. Buccal swab DNA was genotyped for CYP2C9 *2 and CYP2C9 * 3 and VKORC1 C1173T with a rapid assay. Standard dosing followed an empirical protocol, whereas pharmacogenetic-guided dosing followed a regression equation including the 3 genetic variants and age, sex, and weight. Prothrombin time international normalized ratio (INR) was measured routinely on days 0, 3, 5, 8, 21, 60, and 90. A research pharmacist unblinded to treatment strategy managed dose adjustments. Patients were followed up for up to 3 months. Pharmacogenetic-guided predicted doses more accurately approximated stable doses ( P <0.001), resulting in smaller ( P =0.002) and fewer ( P =0.03) dosing changes and INRs ( P =0.06). However, percent out-of-range INRs (pharmacogenetic=30.7%, standard=33.1%), the primary end point, did not differ significantly between arms. Despite this, when restricted to wild-type patients (who required larger doses; P =0.001) and multiple variant carriers (who required smaller doses; P <0.001) in exploratory analyses, results (pharmacogenetic=29%, standard=39%) achieved nominal significance ( P =0.03). Multiple variant allele carriers were at increased risk of an INR of ≥4 ( P =0.03). Conclusions— An algorithm guided by pharmacogenetic and clinical factors improved the accuracy and efficiency of warfarin dose initiation. Despite this, the primary end point of a reduction in out-of-range INRs was not achieved. In subset analyses, pharmacogenetic guidance showed promise for wild-type and multiple variant genotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L., & Rettie, A. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044503 · Cited by 1,399
Aithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,243
Higashi, M. K. (2002) · JAMA · doi:10.1001/jama.287.13.1690 · Cited by 1,048
Sconce, E. A., Khan, T. I., Wynne, H. A., Avery, P., Monkhouse, L., King, B. P., Wood, P., Kesteven, P., Daly, A. K., & Kamali, F. (2005) · Blood · doi:10.1182/blood-2005-03-1108 · Cited by 947
A physical map of the human genome
The International Human Genome Mapping Consortium, Washington University School of Medicine, G. S. C., McPherson, J. D., Marra, M., Hillier, L., Waterston, R. H., Chinwalla, A., Wallis, J., Sekhon, M., Wylie, K., et al. (2001) · Nature · doi:10.1038/35057157 · Cited by 925
Hylek, E. M., Skates, S. J., Sheehan, M. A., & Singer, D. E. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608223350802 · Cited by 789
Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism
(1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371001 · Cited by 784
D'Andrea, G., D'Ambrosio, R. L., Di Perna, P., Chetta, M., Santacroce, R., Brancaccio, V., Grandone, E., & Margaglione, M. (2005) · Blood · doi:10.1182/blood-2004-06-2111 · Cited by 699
Guttmacher, A. E., & Collins, F. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmra012240 · Cited by 629
(1997) · ACC Current Journal Review · doi:10.1016/s1062-1458(97)83303-x · Cited by 539
Bovill, E. G., Terrin, M. L., Stump, D. C., Berke, A. D., Frederick, M., Collen, D., Feit, F., Gore, J. M., Hillis, L. D., Lambrew, C. T., et al. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-4-256 · Cited by 479
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
Wadelius, M., Chen, L. Y., Downes, K., Ghori, J., Hunt, S., Eriksson, N., Wallerman, O., Melhus, H., Wadelius, C., Bentley, D., et al. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500313 · Cited by 468
Association of warfarin dose with genes involved in its action and metabolism
Wadelius, M., Chen, L. Y., Eriksson, N., Bumpstead, S., Ghori, J., Wadelius, C., Bentley, D., McGinnis, R., & Deloukas, P. (2007) · Human Genetics · doi:10.1007/s00439-006-0260-8 · Cited by 390
Takahashi, H., Wilkinson, G. R., Nutescu, E. A., Morita, T., Ritchie, M. D., Scordo, M. G., Pengo, V., Barban, M., Padrini, R., Ieiri, I., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000184955.08453.a8 · Cited by 376
Sanderson, S., Emery, J., & Higgins, J. (2005) · Genetics in Medicine · doi:10.1097/01.gim.0000153664.65759.cf · Cited by 363
Caraco, Y., Blotnick, S., & Muszkat, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100316 · Cited by 360
Pharmacogenomics: Unlocking the Human Genome for Better Drug Therapy
McLeod, H. L., & Evans, W. E. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.101 · Cited by 331
Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
Eby, C., Milligan, P. E., Banet, G. A., Duncan, J., McLeod, H. L., & Gage, B. F. (2003) · Thrombosis and Haemostasis · doi:10.1160/th03-06-0379 · Cited by 322
Kimmel, S. E. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.3.229 · Cited by 290
AQUILANTE, C., LANGAEE, T., LOPEZ, L., YARANDI, H., TROMBERG, J., MOHUCZY, D., GASTON, K., WADDELL, C., CHIRICO, M., & JOHNSON, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.11.011 · Cited by 266
Crespi, C. L., & Miller, V. P. (1997) · Pharmacogenetics · doi:10.1097/00008571-199706000-00005 · Cited by 264
CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates
Takanashi, K., Tainaka, H., Kobayashi, K., Yasumori, T., Hosakawa, M., & Chiba, K. (2000) · Pharmacogenetics · doi:10.1097/00008571-200003000-00001 · Cited by 261
Kovacs, M. J., Rodger, M., Anderson, D. R., Morrow, B., Kells, G., Kovacs, J., Boyle, E., & Wells, P. S. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-9-200305060-00007 · Cited by 223
Carlquist, J. F., Horne, B. D., Muhlestein, J. B., Lappé, D. L., Whiting, B. M., Kolek, M. J., Clarke, J. L., James, B. C., & Anderson, J. L. (2006) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-006-9030-7 · Cited by 215
Self-citationHillman, M. A., Wilke, R. A., Yale, S. H., Vidaillet, H. J., Caldwell, M. D., Glurich, I., Berg, R. L., Schmelzer, J., & Burmester, J. K. (2005) · Clinical Medicine & Research · doi:10.3121/cmr.3.3.137 · Cited by 196
Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors
Wadelius, M., Sörlin, K., Wallerman, O., Karlsson, J., Yue, Q.-Y., Magnusson, P. K. E., Wadelius, C., & Melhus, H. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500220 · Cited by 191
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype
Voora, D., Eby, C., Linder, M. W., Milligan, P. E., Bukaveckas, B. L., McLeod, H. L., Maloney, W., Clohisy, J., Burnett, S. R., Grosso, L., et al. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-08-0542 · Cited by 189
Genetic-based dosing in orthopedic patients beginning warfarin therapy
Millican, E. A., Lenzini, P. A., Milligan, P. E., Grosso, L., Eby, C., Deych, E., Grice, G., Clohisy, J. C., Barrack, R. L., Burnett, R. S. J., et al. (2007) · Blood · doi:10.1182/blood-2007-01-069609 · Cited by 178
Low-Molecular-Weight Heparin in the Treatment of Patients With Venous Thromboembolism
(1998) · Journal of Urology · doi:10.1016/s0022-5347(01)63665-6 · Cited by 171
Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal
Odén, A., Fahlén, M., & Hart, R. G. (2006) · Thrombosis Research · doi:10.1016/j.thromres.2004.11.025 · Cited by 163
Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype
Hillman, M. A., Wilke, R. A., Caldwell, M. D., Berg, R. L., Glurich, I., & Burmester, J. K. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114760.08559.dc · Cited by 144
Pharmacogenetics and drug-induced arrhythmias
Roden, D. M. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00302-3 · Cited by 121
The Pharmacogenetics of Coumarin Therapy
Voora, D., McLeod, H. L., Eby, C., et al. (2005) · Pharmacogenomics · doi:10.2217/14622416.6.5.503 · Cited by 98
Cardiovascular Pharmacogenomics: Current Status, Future Prospects
Anderson, J. L., Carlquist, J. F., Home, B. D., & Muhlestein, J. B. (2003) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840300800i110 · Cited by 33
Self-citationPharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements
Gage, B. F., & Milligan, P. E. (2005) · Thrombosis Research · doi:10.1016/j.thromres.2005.06.009 · Cited by 25
Cited by
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
A Prospective Natural-History Study of Coronary Atherosclerosis
Stone, G. W., Maehara, A., Lansky, A. J., de Bruyne, B., Cristea, E., Mintz, G. S., Mehran, R., McPherson, J., Farhat, N., Marso, S. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1002358 · Cited by 3,276
Precision medicine, AI, and the future of personalized health care
Johnson, K. B., Wei, W., Weeraratne, D., Frisse, M. E., Misulis, K., Rhee, K., Zhao, J., & Snowdon, J. L. (2021) · Clinical and Translational Science · doi:10.1111/cts.12884 · Cited by 1,854
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., Steg, P. G., Ferrières, J., Danchin, N., & Becquemont, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808227 · Cited by 1,728
Early Diagnosis of Myocardial Infarction with Sensitive Cardiac Troponin Assays
Reichlin, T., Hochholzer, W., Bassetti, S., Steuer, S., Stelzig, C., Hartwiger, S., Biedert, S., Schaub, N., Buerge, C., Potocki, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900428 · Cited by 1,687
Metadata
- Authors
- Anderson, J. L., Horne, B. D., Stevens, S. M., Grove, A. S., Barton, S., Nicholas, Z. P., Kahn, S. F. S., May, H. T., Samuelson, K. M., Muhlestein, J. B., & Carlquist, J. F.
- Venue
- Circulation
- Published
- 2007-11-27
- Volume
- 116
- Issue
- 22
- Pages
- 2563-2570
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2157065952
- Cited by
- 727
- References
- 37
- FWCI
- 83.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.